Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations
FAP-targeted PET imaging in cancer patients
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more
OncoAlert Colloquium Day 4: GI oncology and EONS
OncoAlert Colloquium Day 3: Breast cancer
OncoAlert Colloquium Day 2: Lung cancer and MASCC